- Home
- OXSQ vs TVRD Comparison
OXSQ vs TVRD Comparison
Compare OXSQ & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXSQ
- TVRD
- Stock Information
- Founded
- OXSQ 2003
- TVRD 2017
- Country
- OXSQ United States
- TVRD United States
- Employees
- OXSQ N/A
- TVRD N/A
- Industry
- OXSQ Blank Checks
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- OXSQ Finance
- TVRD Health Care
- Exchange
- OXSQ Nasdaq
- TVRD Nasdaq
- Market Cap
- OXSQ 175.6M
- TVRD 246.5M
- IPO Year
- OXSQ N/A
- TVRD N/A
- Fundamental
- Price
- OXSQ $2.33
- TVRD $28.34
- Analyst Decision
- OXSQ
- TVRD Strong Buy
- Analyst Count
- OXSQ 0
- TVRD 2
- Target Price
- OXSQ N/A
- TVRD $52.00
- AVG Volume (30 Days)
- OXSQ 586.2K
- TVRD 48.4K
- Earning Date
- OXSQ 04-25-2025
- TVRD 05-13-2025
- Dividend Yield
- OXSQ 18.03%
- TVRD N/A
- EPS Growth
- OXSQ N/A
- TVRD N/A
- EPS
- OXSQ N/A
- TVRD N/A
- Revenue
- OXSQ $42,166,831.00
- TVRD N/A
- Revenue This Year
- OXSQ N/A
- TVRD N/A
- Revenue Next Year
- OXSQ N/A
- TVRD N/A
- P/E Ratio
- OXSQ N/A
- TVRD N/A
- Revenue Growth
- OXSQ N/A
- TVRD N/A
- 52 Week Low
- OXSQ $2.28
- TVRD $8.13
- 52 Week High
- OXSQ $3.13
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- OXSQ 30.73
- TVRD N/A
- Support Level
- OXSQ $2.31
- TVRD N/A
- Resistance Level
- OXSQ $2.39
- TVRD N/A
- Average True Range (ATR)
- OXSQ 0.04
- TVRD 0.00
- MACD
- OXSQ -0.01
- TVRD 0.00
- Stochastic Oscillator
- OXSQ 10.53
- TVRD 0.00
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.